Denali Therapeutics Inc. DNLI Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -49.6%-3.9pp | -45.7%-1.3pp | -44.4%-4.8pp | -39.7%-4.5pp | -35.2%+2.2pp | |
| Return on assets | -40%+0.7pp | -40.7%-0.9pp | -39.7%-3.8pp | -35.9%-4.1pp | -31.8%+1.6pp | |
| Return on invested capital | -64.8%-8.0pp | -56.8%-6.0pp | -50.8%-4.2pp | -46.6%-6.3pp | -40.3%+7.0pp | |
| Liquidity | ||||||
| Current ratio | 9.3×+0.1× | 9.2×-0.6× | 9.8×-0.5× | 10.3×+0.7× | 9.6×+1.1× | |
| Quick ratio | 9.3×+0.1× | 9.2×-0.6× | 9.8×-0.5× | 10.3×+0.7× | 9.6×+1.1× | |
| Cash ratio | 3.5×+1.4× | 2.1×+1.1× | 1×-0.5× | 1.6×+0.9× | 0.7×-1.1× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $4.96-15.5% | $5.87+9.3% | $5.37-10.3% | $5.99-8.6% | $6.56-12.3% | |
| Valuation | ||||||
| Market capitalization | $3.04B+18.1% | $2.58B+21.4% | $2.12B+1.5% | $2.09B+6.0% | $1.97B-32.7% | |
| Enterprise value | $2.69B+11.7% | $2.41B+16.3% | $2.07B+3.9% | $2B+1.5% | $1.97B-30.1% | |
| Price / book | 3.3×+0.7× | 2.5×+0.3× | 2.3×+0.3× | 2×+0.3× | 1.8×-0.6× | |
| Free cash flow yield | -13.8%+2.6pp | -16.4%+3.0pp | -19.4%-1.8pp | -17.6%+1.9pp | -19.5%-7.1pp | |
| Earnings yield | -16.7%+3.2pp | -19.9%+3.6pp | -23.5%-0.6pp | -22.9%+0.1pp | -23%-8.6pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Denali Therapeutics Inc.'s ratios come from?
- Every ratio is computed from Denali Therapeutics Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.